Korea University Study Reveals How a Blood Biomarker Tracks Response to Lecanemab in Early Alzheimer's Disease (Yahoo Finance) - Sep 14, 2026 - "Of the 153 patients, 81 had complete p-tau217 measurements at baseline, 3 months, and 6 months and were included in the analysis of distinct biomarker response patterns. Cognitive assessments were followed for 12 months...The researchers also found that baseline hypertension was independently associated with a weaker p-tau217 response. The greater-reduction group included 29 patients, compared with 52 in the lesser-reduction group. Hypertension was present in 10.3% of patients in the greater-reduction group and 42.3% of those in the lesser-reduction group...The greater-reduction group showed more favorable MMSE trajectories, while CDR-SB scores increased more slowly than in the lesser-reduction group. The difference in CDR-SB trajectories between groups was statistically significant (p < 0.001)."
Real-world • Alzheimer's Disease
|